Physician profile
Kathryn A Polovitz
NPI 1457557191
$402,741.14
in general payments reported to CMS, 2019-2025
71 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $50K · 2021: $51K · 2022: $76K · 2023: $68K · 2024: $58K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Travel and Lodging: $17K · Food and Beverage: $7,324 · Honoraria: $4,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,916.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,112.00 |
| Travel and Lodging | $17,188.54 |
| Food and Beverage | $7,324.17 |
| Honoraria | $4,016.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $379,107.20 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Greenwich Biosciences, INC. | $11,729.02 | 2019-2021 | |
| Ucb, INC. | $1,039.99 | 2019-2023 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $715.71 | 2019-2023 | |
| Allergan, INC. | $604.30 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $599.28 | 2019-2023 | Ongentys, Ingrezza |
| Sk Life Science, INC. | $475.57 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $462.99 | 2019-2022 | |
| Eisai INC. | $430.52 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $413.80 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $403.29 | 2022 | |
| Supernus Pharmaceuticals, INC. | $394.42 | 2019-2022 | |
| Amgen INC. | $386.31 | 2019-2023 | Aimovig |
| Celgene Corporation | $369.29 | 2020-2023 | Zeposia |
| Biogen, INC. | $317.52 | 2019-2022 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Polovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.